Advanced aggressive fibromatosis: Effective palliation with chemotherapy
| Autor: | Constantinidou, Anastasia, Jones, Robin Lewis, Scurr, Michelle R., Al-Muderis, Omar, Judson, Ian Robert |
|---|---|
| Přispěvatelé: | Constantinidou, Anastasia [0000-0001-5316-7574], Judson, Ian Robert [0000-0002-4766-5304] |
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty Palliative care Adolescent medicine.medical_treatment Vinblastine Polyethylene Glycols Young Adult Antineoplastic Combined Chemotherapy Protocols medicine Humans Neoplasm Invasiveness Radiology Nuclear Medicine and imaging Doxorubicin Registries Child Retrospective Studies Chemotherapy business.industry Palliative Care Fibromatosis Hematology General Medicine Middle Aged medicine.disease Surgery Radiography Fibromatosis Aggressive Methotrexate Treatment Outcome Oncology Abdominal Neoplasms Child Preschool Aggressive fibromatosis Disease Progression Hormonal therapy Female Sarcoma business Progressive disease medicine.drug |
| Zdroj: | Acta Oncologica |
| ISSN: | 1651-226X 0284-186X |
| Popis: | Background. Aggressive fibromatosis (AF) is a locally invasive proliferative disease. The mainstay of treatment is surgery. Chemotherapy may be considered in inoperable AF following failure of hormonal therapy and/or NSAIDs. Material and methods. We conducted a retrospective search of the prospectively maintained Royal Marsden Hospital Sarcoma Unit database to identify patients with AF treated with chemotherapy between 1987 and 2009. Results. Thirty-nine patients, thirty one females and eight males, received one or more lines of chemotherapy. The most frequently employed chemotherapy regimens were methotrexate/vinblastine [MTX/VBL] (18) and pegylated liposomal doxorubicin [PLD] (14). MTX/VBL was administered weekly or every two weeks at MTX 50 mg and VBL 10 mg. Treatment duration ranged from three weeks to one year with a median of 4.5 months. Partial response (PR) was observed in 11% of cases, disease stabilisation (SD) in 60% and progressive disease (PD) in 22%. Time to progression ranged from one month to sixteen years. The main toxicities reported were mucositis (4), peripheral neuropathy (3), vomiting (3), and neutropenia (3). PLD was administered at 40-50 mg/m2 every four weeks, for up to six cycles. PR was achieved in 33% and in the remainder the disease was stable with no progression during treatment. Three (25%) patients have so far progressed after treatment. Symptomatic benefit, especially pain relief, was reported in 86% (12/14) of cases. Main toxicities included palmar plantar erythema (5) and mucositis (4). Discussion. MTX/VBL remains a useful combination but PLD is emerging as a well tolerated and effective systemic therapy in advanced AF. © 2011 Informa Healthcare. 50 3 455 461 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|